• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对最重要的血管生成细胞受体——血管内皮生长因子受体2的双体的表达、纯化及特性分析

Expression, purification, and characterization of a diabody against the most important angiogenesis cell receptor: Vascular endothelial growth factor receptor 2.

作者信息

Behdani Mahdi, Zeinali Sirous, Karimipour Morteza, Khanahmad Hossein, Asadzadeh Nader, Azadmanesh Kayhan, Seyed Negar, Baniahmad Seyed Farzad, Anbouhi Mahdi Habibi

机构信息

Department of Molecular Medicine, Pasteur Institute of Iran, Tehran, Iran.

出版信息

Adv Biomed Res. 2012;1:34. doi: 10.4103/2277-9175.100126. Epub 2012 Aug 28.

DOI:10.4103/2277-9175.100126
PMID:23326765
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3544076/
Abstract

Antibodies and their derivative fragments have long been used as tools in a variety of applications, in fundamental research work, biotechnology, diagnosis, and therapy. Camels produce single heavy-chain antibodies (VHH) in addition to usual antibodies. These minimal-sized binders are very robust and bind the antigen with high affinity in a monomeric state. Vascular endothelial growth factor recepror-2 (VEGFR2) is an important tumor-associated receptor that blockade of its signaling can lead to the inhibition of neovascularization and tumor metastasis. Here, we describe the construction, expression, and purification VEGFR2-specific Diabody. Two variable fragments of a same camel anti-VEGFR2 antibody were linked together by the upper hinge segment of antibody to make a diabody. We showed the ability of diabody to recognition of VEGFR2 on the cell surface by FACS. Diabodies can be produced in the low-cost prokaryotic expression system, so they are suitable molecules for diagnostic and therapeutic issues.

摘要

抗体及其衍生片段长期以来一直被用作各种应用中的工具,包括基础研究工作、生物技术、诊断和治疗。骆驼除了产生常规抗体外,还产生单链重抗体(VHH)。这些最小尺寸的结合物非常稳定,以单体状态与抗原高亲和力结合。血管内皮生长因子受体-2(VEGFR2)是一种重要的肿瘤相关受体,阻断其信号传导可导致新血管形成和肿瘤转移的抑制。在这里,我们描述了VEGFR2特异性双体的构建、表达和纯化。同一骆驼抗VEGFR2抗体的两个可变片段通过抗体的上铰链段连接在一起,形成一个双体。我们通过荧光激活细胞分选术(FACS)展示了双体识别细胞表面VEGFR2的能力。双体可以在低成本的原核表达系统中产生,因此它们是适用于诊断和治疗问题的分子。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8fd/3544076/95a4f4c0038f/ABR-1-34-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8fd/3544076/5cb05d31f857/ABR-1-34-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8fd/3544076/9bda41f30287/ABR-1-34-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8fd/3544076/ba0abaa915b0/ABR-1-34-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8fd/3544076/95a4f4c0038f/ABR-1-34-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8fd/3544076/5cb05d31f857/ABR-1-34-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8fd/3544076/9bda41f30287/ABR-1-34-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8fd/3544076/ba0abaa915b0/ABR-1-34-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8fd/3544076/95a4f4c0038f/ABR-1-34-g004.jpg

相似文献

1
Expression, purification, and characterization of a diabody against the most important angiogenesis cell receptor: Vascular endothelial growth factor receptor 2.针对最重要的血管生成细胞受体——血管内皮生长因子受体2的双体的表达、纯化及特性分析
Adv Biomed Res. 2012;1:34. doi: 10.4103/2277-9175.100126. Epub 2012 Aug 28.
2
A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3.一种重组的、全人源双特异性抗体可中和由血管内皮生长因子受体2和3介导的生物学活性。
Mol Cancer Ther. 2005 Mar;4(3):427-34. doi: 10.1158/1535-7163.MCT-04-0261.
3
Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor.生成并鉴定针对血管内皮生长因子受体-2(血管生成细胞受体)的功能性纳米抗体。
Mol Immunol. 2012 Feb;50(1-2):35-41. doi: 10.1016/j.molimm.2011.11.013. Epub 2011 Dec 29.
4
Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2.针对血管内皮生长因子受体2上两个不同表位的双特异性双抗体的获得性拮抗活性。
J Immunol Methods. 1999 Nov 19;230(1-2):159-71. doi: 10.1016/s0022-1759(99)00135-0.
5
Generation and characterization of a human nanobody against VEGFR-2.一种抗血管内皮生长因子受体-2人源纳米抗体的产生与鉴定
Acta Pharmacol Sin. 2016 Jun;37(6):857-64. doi: 10.1038/aps.2016.2. Epub 2016 Apr 25.
6
Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.利用一种针对血管内皮生长因子(VEGF)激酶受体(fms样酪氨酸激酶受体和含激酶插入结构域的受体)的双功能双抗体完全抑制VEGF活性。
Cancer Res. 2001 Oct 1;61(19):7002-8.
7
A novel bispecific diabody targeting both vascular endothelial growth factor receptor 2 and epidermal growth factor receptor for enhanced antitumor activity.一种新型双特异性双抗体,靶向血管内皮生长因子受体2和表皮生长因子受体,以增强抗肿瘤活性。
Biotechnol Prog. 2016 Mar;32(2):294-302. doi: 10.1002/btpr.2231. Epub 2016 Feb 13.
8
Construction and expression of an anti-VEGFR2 Nanobody-Fc fusionbody in NS0 host cell.抗血管内皮生长因子受体2纳米抗体-Fc融合体在NS0宿主细胞中的构建与表达
Protein Expr Purif. 2016 Jul;123:19-25. doi: 10.1016/j.pep.2016.03.004. Epub 2016 Mar 17.
9
Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.二价抗ErbB2双抗体片段对肿瘤细胞的靶向作用与抗体的固有亲和力无关。
Cancer Res. 2000 Nov 15;60(22):6434-40.
10
Development and characterization of an αvβ6-specific diabody and a disulfide-stabilized αvβ6-specific cys-diabody.一种αvβ6特异性双抗体和二硫键稳定的αvβ6特异性半胱氨酸双抗体的开发与表征。
Nucl Med Biol. 2015 Dec;42(12):945-57. doi: 10.1016/j.nucmedbio.2015.07.014. Epub 2015 Aug 4.

引用本文的文献

1
Designing and Development of a Tandem Bivalent Nanobody against VEGF.一种抗血管内皮生长因子串联双价纳米抗体的设计与开发
Avicenna J Med Biotechnol. 2021 Apr-Jun;13(2):58-64. doi: 10.18502/ajmb.v13i2.5519.
2
Intrabody targeting vascular endothelial growth factor receptor-2 mediates downregulation of surface localization.靶向血管内皮生长因子受体-2的胞内抗体介导表面定位下调。
Cancer Gene Ther. 2017 Jan;24(1):33-37. doi: 10.1038/cgt.2016.76. Epub 2016 Dec 16.

本文引用的文献

1
Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor.生成并鉴定针对血管内皮生长因子受体-2(血管生成细胞受体)的功能性纳米抗体。
Mol Immunol. 2012 Feb;50(1-2):35-41. doi: 10.1016/j.molimm.2011.11.013. Epub 2011 Dec 29.
2
Tanibirumab (TTAC-0001): a fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2).坦尼布单抗(TTAC-0001):一种完全人源化单克隆抗体,靶向血管内皮生长因子受体 2(VEGFR-2)。
Arch Pharm Res. 2011 Aug;34(8):1223-6. doi: 10.1007/s12272-011-0821-9.
3
An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding.
一种针对 VEGFR-2 Ig 结构域 4-7 的抗体可抑制 VEGFR-2 的激活和 VEGFR-2 依赖性血管生成,而不影响配体结合。
Mol Cancer Ther. 2011 May;10(5):770-83. doi: 10.1158/1535-7163.MCT-10-0876. Epub 2011 Mar 9.
4
Nanobody; an old concept and new vehicle for immunotargeting.纳米抗体;免疫靶向的老概念和新载体。
Immunol Invest. 2011;40(3):299-338. doi: 10.3109/08820139.2010.542228. Epub 2011 Jan 11.
5
Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2.雷莫芦单抗(IMC-1121B):血管内皮生长因子受体-2 的单克隆抗体抑制物。
Curr Oncol Rep. 2011 Apr;13(2):97-102. doi: 10.1007/s11912-010-0149-5.
6
Therapeutic antibodies: successes, limitations and hopes for the future.治疗性抗体:成功、局限与未来展望
Br J Pharmacol. 2009 May;157(2):220-33. doi: 10.1111/j.1476-5381.2009.00190.x.
7
Applications of single-chain variable fragment antibodies in therapeutics and diagnostics.单链可变片段抗体在治疗和诊断中的应用。
Biotechnol Adv. 2009 Jul-Aug;27(4):502-20. doi: 10.1016/j.biotechadv.2009.04.004. Epub 2009 Apr 15.
8
Camelid immunoglobulins and nanobody technology.骆驼科动物免疫球蛋白与纳米抗体技术。
Vet Immunol Immunopathol. 2009 Mar 15;128(1-3):178-83. doi: 10.1016/j.vetimm.2008.10.299. Epub 2008 Oct 17.
9
Single-domain antibodies as building blocks for novel therapeutics.作为新型治疗药物构建单元的单域抗体。
Curr Opin Pharmacol. 2008 Oct;8(5):600-8. doi: 10.1016/j.coph.2008.07.006. Epub 2008 Aug 22.
10
VEGF-targeted therapy: mechanisms of anti-tumour activity.血管内皮生长因子靶向治疗:抗肿瘤活性机制
Nat Rev Cancer. 2008 Aug;8(8):579-91. doi: 10.1038/nrc2403. Epub 2008 Jul 3.